

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Abbisko Cayman Limited**  
**和譽開曼有限責任公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2256)**

## **VOLUNTARY ANNOUNCEMENT**

### **2024 ESMO-GI | ABBISKO THERAPEUTICS PRESENTS NEW PHASE II CLINICAL DATA OF IRPAGRATINIB IN COMBINATION WITH ATEZOLIZUMAB FOR ADVANCED HEPATOCELLULAR CARCINOMA**

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced that it has presented new phase II clinical trial data of its self-developed highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) at the 2024 ESMO-GI Congress. The presentation highlights that 220mg BID of irpagratinib in combination with atezolizumab demonstrated promising efficacy with an objective response rate (ORR) of 50% in FGF19 + HCC patients.

This is a voluntary announcement made by the Company. The Group cannot guarantee that irpagratinib (ABSK011) will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Abbisko Cayman Limited**  
**Dr. Xu Yao-Chang**  
*Chairman*

Shanghai, June 28, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.*

## **2024 ESMO-GI | Abbisko Therapeutics presents new phase II clinical data of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma**

On June 28, 2024, Abbisko Therapeutics announced that it has presented new phase II clinical trial data of its self-developed highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) at the 2024 ESMO-GI Congress. The presentation highlights that 220mg BID of irpagratinib in combination with atezolizumab demonstrated promising efficacy with an objective response rate (ORR) of 50% in FGF19 + HCC patients.

ESMO-GI, a world-renowned gastrointestinal oncology conference, is being held in Munich, Germany, from June 26 to 29, 2024.

Abbisko Therapeutics presentations at ESMO-GI 2024:

**Title: A Phase II Study of Irpagratinib (ABSK-011) plus Atezolizumab in Patients with Advanced Hepatocellular Carcinoma (HCC)**

**Poster display number:** 171P

**Poster display session:** Hepatocellular and non-biliary liver cancer

**Poster display date and time:** June 27, 2024, 15:35-16:30 PM (UTC+1)

### **Summary:**

At the 2024 ESMO-GI conference, Abbisko Therapeutics debuted new phase II clinical trial results with the combination of irpagratinib and atezolizumab. In HCC patients with FGF19 overexpression, the objective response rate (ORR) was 50% (5/10) in the 220mg BID cohort, demonstrating this novel combination therapy has notable benefits in enhancing the ORR. Notably, strong efficacy and good safety were also observed in the combination therapy for patients who had previously received immune checkpoint inhibitor (ICI) therapy, providing further evidence that this novel mechanism targeting FGF19-FGFR4 may provide a much-needed differentiated treatment option for HCC.

Given the encouraging preliminary results from this study, Abbisko Therapeutics plans to explore dual/triple combinations with irpagratinib in earlier stage of HCC. Abbisko Therapeutics continues to look forward to combination approaches with irpagratinib to better address HCC and bring hope to patients, with aims to conduct further research and innovation in this area.

### **Background:**

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and ranks as the sixth most prevalent cancer and third leading cause of death worldwide. Dysregulation of FGF19-FGFR4 signaling accounts for approximately 30% of HCC and plays a pivotal role in driving HCC tumorigenesis. Irpagratinib is a highly potent and selective FGFR4 inhibitor, with potential to become a first-in-class or best-in-class FGFR4 inhibitor.

Abbisko Therapeutics previously presented clinical data from its first-in-human study of irpagratinib at the 2023 ESMO Annual Meeting, demonstrating promising anti-tumor activity with an ORR of 40.7% in FGF19 overexpressed late-line HCC patients treated with BID.

To further explore the therapeutic potential of irpagratinib, Abbisko Therapeutics is conducting a phase II clinical trial of irpagratinib in combination with atezolizumab, a PD-L1 antibody, in FGF19 + advanced HCC patients, to understand safety and efficacy of such combination therapy.

### **About Abbisko Therapeutics**

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to the discovery and development of innovative medicines that treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology.

Please visit [www.abbisko.com](http://www.abbisko.com) for more information.

### **Forward-Looking Statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.